Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug. It came with a $1 million upfront fee to the medicine's originator, Tanabe Pharma.
Jon Congleton, Mineralys Therapeutics CEO
June 3, 2026 10:32 AM EDT
Financing
Mineralys makes money moves before looming hypertension approval
Kyle LaHucik
Cytokinetics executives said their first FDA-approved drug is off to a strong start as it goes up against its Bristol Myers…
The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment…
Crystalys Therapeutics raises $130M Series B, led by Frazier Life Sciences, to bring gout drug dotinurad to US/EU markets. The…
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a…
Biohaven's Phase 2 trial of its muscle-building product taldefgrobep alfa will read out later this year, with Eli Lilly’s similar…
City banks nearly $100M for next-gen RNAi drugs
